Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods
WO2006015183A2
Pharmaceutical compositions for treating disorders of the skin
US2005272804A1
Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
CA2508585A1
Transdermal delivery system for treatment of cognitive disorders
WO2005089746A1
Dosage titration for treatment of cognitive disorders
US2009118347A1
Method of treating Down syndrome
WO2005092009A2
Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
AU2005215788A1
Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo(2,3-b)indol-5-yl phenylcarbamate
CA2553033A1
Methods for treatment of complications of diabetes
BRPI0402756A
method for treating cognitive disorders
BRPI0402757A
test method
CA2465600A1
Dosage titration for treatment of cognitive disorders
CA2489350A1
Method for identifying drugs for the treatment of alzheimer's disease
AU2003243659A1
Method for identifying drugs for the treatment of Alzheimer's disease
BR0306855A
Method for the treatment of cognitive disorders
WO02059619A2
Method for the diagnosis of alzheimer's disease
US6495700B1
Process for producing phenserine and its analog
BR0109915A
Diagnostic test for alzheimer's disease
US6689753B1
β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
IL149392D0
PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
